FirstSignal™
Biological Operating System
MG-LZ8™ is the first signal
the body needs to hear.
Every signalling pathway depends on a clear input. MG-LZ8™ is that input — restoring immune coherence at the receptor level before any downstream amplification is attempted. Signal first. Response follows.
"The immune system is not a department. It is the operating system."
238×
IL-2 Amplification
+51.7%
Phagocytosing Neutrophils
348×
Combined Potency Factor
4
Protocol Tiers
0
Cytotoxicity Recorded
The Mechanism
Immune restoration is not a claim.
It is a measured outcome.
Three independent evidence pillars underpin every FirstSignal™ protocol. Each anchors to MG-LZ8™ — a dual-phase extract of Ganoderma sichuanense Zhao & Zhang, cultivated in antler morphology by Mushroom Guru (Pty) Ltd.
What is IL-2? Interleukin-2 (IL-2) is a cytokine — a chemical messenger that immune cells use to communicate with each other. Think of it as the mobilisation order of the immune system. When IL-2 is released, it signals T-cells and Natural Killer (NK) cells to divide, multiply, and become active defenders. Without sufficient IL-2, the immune system cannot mount a coordinated response. It is the difference between an immune system on standby and one that is actively, intelligently defending.
The outcome: At 100 μg, MG-LZ8™ drives IL-2 production at 238× above baseline — confirmed by Prof. Václav Větvíčka at the University of Louisville under blinded conditions against commercial comparators. Simultaneously, phagocytosing neutrophils — the immune cells that physically engulf and destroy pathogens — increased from 31.1% to 47.2% (+51.7%). Zero cytotoxicity was recorded at all tested concentrations. No other tested comparator came close to these figures. Větvíčka V. (2018). University of Louisville pre-clinical evaluation of MG-LZ8™.
The outcome: At 100 μg, MG-LZ8™ drives IL-2 production at 238× above baseline — confirmed by Prof. Václav Větvíčka at the University of Louisville under blinded conditions against commercial comparators. Simultaneously, phagocytosing neutrophils — the immune cells that physically engulf and destroy pathogens — increased from 31.1% to 47.2% (+51.7%). Zero cytotoxicity was recorded at all tested concentrations. No other tested comparator came close to these figures. Větvíčka V. (2018). University of Louisville pre-clinical evaluation of MG-LZ8™.
Not just on the tongue. Taste receptor type 2 (T2R) bitter receptors were once assumed to exist only on the tongue. Research confirmed in Gopallawa et al. (2021) overturned this entirely: T2R receptors are expressed on virtually every immune cell in the body — neutrophils, macrophages, dendritic cells, and T-cells all carry them. This means every immune cell has a direct receptor for bitter compounds, enabling a system-wide immune response independent of the digestive pathway.
Why this matters: When MG-LZ8™ activates T2R receptors, it is signalling directly to the immune system at the cellular level across the entire body — not just in the gut. This is a third, fully independent activation pathway operating alongside Dectin-1 and TLR2. Three separate immune entry points. One extract. No other commercially available Ganoderma product has been shown to activate all three simultaneously.
Why this matters: When MG-LZ8™ activates T2R receptors, it is signalling directly to the immune system at the cellular level across the entire body — not just in the gut. This is a third, fully independent activation pathway operating alongside Dectin-1 and TLR2. Three separate immune entry points. One extract. No other commercially available Ganoderma product has been shown to activate all three simultaneously.
A protein that exists nowhere else in nature. LZ-8 is a 13 kDa immunomodulatory protein found exclusively in Ganoderma species — it does not exist in any other known organism. But what makes it truly remarkable is this: the genomic structure of LZ-8 bears significant sequence homology with human proteins involved in immune regulation. In plain terms, the Ganoderma genome appears to have encoded a protein that the human immune system already knows how to read.
This is not coincidence. It reflects what researchers believe is millions of years of co-evolutionary interaction between fungi and the immune systems of the organisms in their environment. The result is a protein that human immune cells recognise and respond to as if it were their own — activating FOXP3+ regulatory T-cells, restoring mucosal tight junction integrity (via Claudin-1), and rebalancing immune responses that have become dysregulated.
In practice: PMC3707273 (Hsu et al.) confirms FOXP3+ Treg induction via the CD45/CD18/IL-2 pathway. Lin & Hsu (2023, PMC10094145) confirm Claudin-1 restoration after CPT-11-induced gut damage. The mucosal lining of the gut — the body's largest immune organ — is rebuilt by a protein only Ganoderma produces.
This is not coincidence. It reflects what researchers believe is millions of years of co-evolutionary interaction between fungi and the immune systems of the organisms in their environment. The result is a protein that human immune cells recognise and respond to as if it were their own — activating FOXP3+ regulatory T-cells, restoring mucosal tight junction integrity (via Claudin-1), and rebalancing immune responses that have become dysregulated.
In practice: PMC3707273 (Hsu et al.) confirms FOXP3+ Treg induction via the CD45/CD18/IL-2 pathway. Lin & Hsu (2023, PMC10094145) confirm Claudin-1 restoration after CPT-11-induced gut damage. The mucosal lining of the gut — the body's largest immune organ — is rebuilt by a protein only Ganoderma produces.
All scientific claims anchor to MG-LZ8™ — dual-phase extract of Ganoderma sichuanense Zhao & Zhang, cultivated in antler morphology by Mushroom Guru (Pty) Ltd, Strand, Western Cape.
Genomic confirmation: Inqaba Biotechnical SA2025/195735 · ITS 99.69% · EF1-alpha 100% · Dr Viljoen & Dr Labuschagne
Extraction validation: Ecogreen Analytics JB25-029-01 (Feb 2025) · Profile confirmed against original validated standard
Extraction validation: Ecogreen Analytics JB25-029-01 (Feb 2025) · Profile confirmed against original validated standard
✦
Where the Protocol Begins
The existing range.
The foundation.
Every FirstSignal™ protocol begins with immune baseline. Click any product to learn more.
MG-LZ8™ Capsules
Oral · Daily Protocol
Standardised dual-phase extract. The systemic foundation. Zero cytotoxicity. Pre-clinically confirmed.
Learn more
TTD Sublingual
Sublingual · 60-Second Hold
Trans-mucosal delivery. No alcohol carrier. The fastest non-injectable route in the range.
Learn more
MG-LZ8™ Skin Serum
Topical · Transdermal
DMSO carrier. Lymphatic entry within seconds. The dermal layer as a systemic signalling interface.
Learn more
These three formats represent the foundation of the FirstSignal™ protocol — available now. The B-OS sub-cut platform is the next architecture: what becomes possible once the baseline signal is established and held.
◯
Sub-Cutaneous Protocol
Phase II — In Development
The platform is being built.
The architecture is already clear.
The B-OS: Biological Operating System is the sub-cut protocol architecture currently in development. MG-LZ8™ and precision peptide stacks will be delivered in calibrated sequence — in the exact order the biology demands. The oral and topical range is the foundation being laid now. The B-OS platform is what becomes possible once that foundation holds.
MG-LZ8™ as the biological base. Immune coherence will precede all peptide amplification. Without a cleared signal, peptide stacks amplify noise. This tier is non-negotiable and cannot be sequenced away — it is the reason the oral and topical range comes first.
BPC-157 as the primary peptide in this tier. Intestinal wall integrity, tendon and ligament regeneration, mucosal architecture restored as a systemic immune interface. Repair will precede optimisation — every time.
Peptide selection mapped to individual metabolic profile. Insulin sensitivity, growth hormone axis, and mitochondrial function addressed in sequence — not in parallel. Sequence is the protocol.
SS-31 (Elamipretide) as the Tier IV compound — inner mitochondrial membrane protection, cardiolipin stabilisation, and ATP production efficiency restored. The deepest tier of the protocol, entered only when Tiers I–III are stabilised and confirmed. MG-LZ8™'s oxidative environment reduction is what makes this tier land. No shortcuts into this tier exist.
The Fifth Dimension
Cognitive Signal Clarity
"MG-LZ8™ neurotropic evidence and the restored immune-neural axis reveal a fifth layer beyond the four tiers — a measurable return of cognitive clarity that emerges when systemic signal-to-noise ratio is restored at the immune level."
Strategic Partnership
Nine compounds.
The building blocks of an integrated protocol.
Frequency Research Compounds brings eight precision sub-cut preparations and one topical compound to market independently — available now through FRC. Each compound is formulated to its own clinical standard. Practitioners can access and work with them directly through Frequency.
Their integration with MG-LZ8™ as the upstream immune foundation — the B-OS: Biological Operating System architecture — is the next phase of this partnership. Click any card to understand the compound and the role it will occupy within the integrated protocol.
METABOLIC
MOTS-c
Mitochondria-derived peptide.
Investigated for mitochondrial-encoded metabolic homeostasis and exercise mimetic effects, metabolic regulation, insulin sensitivity and AMPK activation.
Full compound detail
GLYCEMIC
GLP3-Plus
Advanced metabolic signalling.
A triple-agonist compound designed for research into advanced metabolic tuning.
Full compound detail
10mg
15mg
20mg
30mg
STRUCTURAL
BPC-157
Body Protection Compound.
Utilised in studies regarding systemic tissue regeneration and gastro-protective properties.
Full compound detail
CONSTRUCT
TB-500
Thymosin Beta-4 analogue.
Cell migration, systemic tissue repair, actin polymerisation and angiogenesis.
Full compound detail
ENERGISE
SS-31
Mitochondrial inner membrane.
Elamipretide. Inner mitochondrial membrane protection, ATP production, cardioprotective.
Full compound detail
REVITALISE
GHK-Cu
Copper tripeptide injectable.
Collagen synthesis, wound healing, skin and connective tissue regeneration. Anti-inflammatory gene expression upregulation.
Full compound detail
FOLLICULAR
AHK-Cu Topical
Copper tripeptide topical.
A specialised copper compound formulation provided in a 30ml pump format for topical research.
Full compound detail
RECHARGE
NAD+
Cellular energy coenzyme.
Nicotinamide adenine dinucleotide. Cellular energy restoration, mitochondrial biogenesis, sirtuin activation. Injectable grade, 500mg per vial.
Full compound detail
GROWTH
Ipamorelin
Selective GH secretagogue.
A ghrelin mimetic that stimulates natural growth hormone release without raising cortisol or ACTH — the cleanest GH peptide in the range.
Full compound detail
FRC Dosing Tool
How long will your vial last?
Select your compound.
Select a compound below, then your injection frequency. Supply estimate calculates instantly.
METABOLIC
MOTS-c
STRUCTURAL
BPC-157
CONSTRUCT
TB-500
ENERGISE
SS-31
REVITALISE
GHK-Cu
GLYCEMIC
GLP3-Plus
RECHARGE
NAD+
GROWTH
Ipamorelin
For research and educational purposes only · Not medical advice · Consult a qualified healthcare professional
What Every Preparation Guarantees
⬡
100% Alcohol-Free
Ethanol used in extraction, fully evaporated. No alcohol in final preparation. Non-toxic by design.
✦
Zero Starch
Fruiting body only. No mycelium-on-grain substrate. No polysaccharide inflation from filler material.
◯
ISO & GMP Compliant
Extracted in ISO/GMP certified facilities. Every batch verified against the validated MG-LZ8™ profile.
✦
Fruiting Body Only
Antler-grown Ganoderma sichuanense exclusively. Chitin-free. Water-soluble. 100% bioavailable.
⟨
Direct Enquiry
Begin with the signal.
The platform follows.
The oral and topical MG-LZ8™ range is available now — the immune foundation that every downstream protocol depends on. The B-OS: Biological Operating System sub-cut platform is the architecture being built for practitioners and clinicians who understand that restoration precedes amplification, and that signal precedes response.
[email protected] · FirstSignal™ (Pty) Ltd operates under licence from Mushroom Guru (Pty) Ltd
Regulatory Notice: This product has not been evaluated by SAHPRA | MCC. Not intended to diagnose, treat, cure, or prevent any disease. For practitioner and clinical enquiries only.
Oral · Daily Protocol
MG-LZ8™ Capsules
Standardised Dual-Phase Extract · Mushroom Guru (Pty) Ltd
What it is
Each capsule delivers a standardised dose of MG-LZ8™ dual-phase extract — the concentrated product of antler-morphology Ganoderma sichuanense subjected to sequential hot-water and ethanol extraction. The ethanol phase is fully evaporated in the final product. Zero starch. Zero fillers. Fruiting body only. A single 15 mg dose is the molecular equivalent of 5,400 mg of standard Reishi powder.
Protocol role
The systemic foundation. Take with food for optimal mucosal contact and Dectin-1 engagement along the gut epithelium. Daily use establishes and maintains the immune baseline from which all downstream protocols operate.
Confirmed outcomes
238× IL-2 amplification · Phagocytosing neutrophils: 31.1% → 47.2% (+51.7%) · Zero cytotoxicity at all tested concentrations. Pre-clinical validation: Prof. Václav Větvíčka, University of Louisville (2018).
Oral
Daily
238× IL-2
MG-LZ8™ Foundation
Sublingual · 60-Second Hold
TTD Sublingual
Trans-Mucosal Delivery · No Alcohol Carrier
What it is
A sublingual drop formulation of MG-LZ8™ designed for direct trans-mucosal absorption. The sublingual venous plexus provides rapid vascular entry that bypasses first-pass hepatic metabolism. No alcohol carrier — unlike most sublingual preparations, TTD does not use ethanol as a preservative or penetration enhancer.
Protocol role
Hold 60 seconds under the tongue. The extended contact time allows the sublingual mucosa to absorb active compounds directly into the capillary network. The fastest non-injectable route in the range — preferred when rapid systemic availability is required. Do not swallow during the hold period.
Key specification
No alcohol. 60-second hold is non-negotiable — shorter contact significantly reduces bioavailability. Ensure oral cavity is clean before administration.
Sublingual
Alcohol-Free
Rapid Uptake
MG-LZ8™
Topical · Transdermal
MG-LZ8™ Skin Serum
DMSO Carrier · CHD-FA™ Transport · Lymphatic Entry
What it is
A topical serum combining MG-LZ8™ extract with pharmaceutical-grade DMSO (Dimethyl Sulfoxide) and CHD-FA™ (Carbohydrate Derived Fulvic Acid). DMSO temporarily increases cell membrane permeability, enabling MG-LZ8™ to bypass the stratum corneum and enter the lymphatic system within seconds. CHD-FA™ acts as a natural chelator and transport carrier, delivering up to 60% increased absorption versus unassisted topical application.
Protocol role
Apply a thin layer to clean, dry skin. A warming sensation is the bioactive response — DMSO-mediated membrane permeation confirming active uptake. The dermal layer is a systemic signalling interface, not a cosmetic surface. Apply thin — volume does not increase efficacy. DMSO carries everything present on the skin; ensure the application site is clean before use.
Topical
DMSO Carrier
CHD-FA™
Lymphatic Entry
MG-LZ8™
Frequency Research Compounds · Sub-Cutaneous
MOTS-c + MG-LZ8™
Mitochondrial Open Reading Frame · AMPK Activation · Metabolic Regulation
The peptide
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondria-derived peptide encoded directly in the mitochondrial genome. It activates AMPK — the master metabolic regulator — improving insulin sensitivity, metabolic flexibility, and exercise capacity. Pre-clinical data shows significant extension of metabolic healthspan and protection against diet-induced metabolic dysfunction.
Why MG-LZ8™ comes first
MOTS-c activates AMPK most effectively in a metabolically cleared environment. Chronic immune activation and elevated inflammatory cytokines directly suppress AMPK signalling — the same pathway MOTS-c is designed to amplify. MG-LZ8™’s 238× IL-2 mobilisation reduces systemic inflammatory noise, clearing the metabolic field. MOTS-c then activates the pathway without opposition. The first signal removes the interference.
MOTS-cAMPK ActivationMitochondrial GenomeMetabolic HealthMG-LZ8™ Foundation
Frequency Research Compounds · Sub-Cutaneous
GLP3-Plus + MG-LZ8™
Advanced Metabolic Signalling · Gut-Brain Axis · Insulin Architecture
The peptide
GLP3-Plus is an advanced metabolic signalling compound targeting the gut-brain axis and insulin architecture via incretin and glucagon receptor pathways. It supports appetite regulation, glucose homeostasis, and pancreatic beta-cell function — designed for individuals where metabolic signalling has been compromised by dietary hijacking or chronic hyperinsulinaemia.
Why MG-LZ8™ comes first
The gut epithelium is the primary site of GLP receptor expression. MG-LZ8™’s LZ-8 protein restores Claudin-1 tight junction integrity — rebuilding the mucosal architecture on which GLP3-Plus receptor engagement depends. A disrupted gut wall produces inconsistent and diminished receptor response. MG-LZ8™ restores the substrate. Signal integrity precedes receptor occupancy.
GLP3-PlusGut-Brain AxisIncretin PathwayGlucose HomeostasisMG-LZ8™ Foundation
Frequency Research Compounds · Sub-Cutaneous
BPC-157 + MG-LZ8™
Body Protection Compound · Gut Wall · Tendon & Ligament · VEGFR2 Angiogenesis
The peptide
BPC-157 (Body Protection Compound, 15 amino acids) is a synthetic peptide derived from a protective gastric juice protein. It promotes healing across multiple tissue types — intestinal wall repair, tendon and ligament regeneration, muscle recovery, and angiogenesis via VEGFR2 upregulation. One of the most extensively studied repair peptides with a strong pre-clinical safety profile and systemic distribution.
Why MG-LZ8™ comes first
BPC-157’s primary action sites — the gut wall and musculoskeletal tissue — are the same structures MG-LZ8™ addresses through LZ-8-mediated Claudin-1 restoration. A disrupted mucosal layer generates persistent inflammatory signalling that directly competes with BPC-157’s repair cascades. MG-LZ8™ settles the immune terrain. BPC-157 then rebuilds the architecture on a stable foundation.
BPC-157Gut WallTendon RepairVEGFR2 AngiogenesisMG-LZ8™ Foundation
Frequency Research Compounds · Sub-Cutaneous
TB-500 + MG-LZ8™
Thymosin Beta-4 Analogue · Cell Migration · Systemic Tissue Repair · Actin Polymerisation
The peptide
TB-500 is a synthetic analogue of Thymosin Beta-4, a peptide present in virtually all human cells. It promotes actin polymerisation — enabling cell migration to injury sites — accelerating tissue repair across muscle, tendon, ligament, skin, and cardiac tissue. Its systemic distribution makes it effective for multi-site recovery and chronic inflammatory conditions where localised repair peptides cannot reach.
Why MG-LZ8™ comes first
TB-500’s mechanism depends on the immune system’s ability to direct cell migration accurately to injury sites. Chronic immune dysregulation produces misdirected inflammatory signalling that dilutes TB-500’s cell migration effect. MG-LZ8™’s 238× IL-2 amplification and neutrophil mobilisation restore immune directionality — TB-500 then operates within a coherent immune scaffold.
TB-500Cell MigrationActin PolymerisationSystemic RepairMG-LZ8™ Foundation
Frequency Research Compounds · Sub-Cutaneous
SS-31 + MG-LZ8™
Elamipretide · Mitochondrial Inner Membrane · Cardiolipin · ATP Production
The peptide
SS-31 (Elamipretide) is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane (IMM), where it binds cardiolipin — the phospholipid critical to the electron transport chain. By stabilising cardiolipin and cristae architecture, SS-31 reduces mitochondrial reactive oxygen species (ROS), restores ATP production efficiency, and prevents mitochondrial permeability transition.
Why MG-LZ8™ comes first
Mitochondrial dysfunction is compounded by chronic immune activation — pro-inflammatory cytokines directly impair electron transport chain efficiency and amplify mitochondrial ROS load. MG-LZ8™’s three-pathway MPO modulation reduces the systemic oxidative environment in which mitochondria operate. SS-31 then targets the inner membrane in a measurably less hostile redox environment.
SS-31Mitochondrial IMMCardiolipinATP ProductionMG-LZ8™ Foundation
Frequency · Follicular Compound · Topical
AHK-Cu Topical
Ala-His-Lys Copper Tripeptide · Follicular Stimulation · Collagen Synthesis
The compound
AHK-Cu (Alanyl-Histidyl-Lysine + Copper) is a copper tripeptide complex with established follicular biology activity. Copper-bound tripeptides activate follicle stimulating growth factors, increase hair follicle size, prolong the anagen (growth) phase, and stimulate collagen and glycosaminoglycan synthesis in the dermal matrix.
The systemic dimension
Follicular health reflects systemic immune status. Hair follicle cycling is directly modulated by immune cells in the follicular bulge. MG-LZ8™’s immune restoration reduces the systemic inflammatory environment that suppresses follicular cycling and prolongs the telogen (resting) phase. AHK-Cu then engages the follicle topically, on terrain that MG-LZ8™ has already cleared. Signal first. Growth follows.
AHK-CuTopicalCopper TripeptideAnagen PhaseMG-LZ8™ Foundation
Frequency Research Compounds · Sub-Cutaneous
GHK-Cu + MG-LZ8™
Glycyl-L-Histidyl-L-Lysine Copper · Collagen Synthesis · Tissue Regeneration · Gene Expression
The compound
GHK-Cu (Glycyl-L-Histidyl-L-Lysine + Copper) is a naturally occurring copper complex found in human plasma, saliva, and urine. It activates over 4,000 human genes, the majority of which are involved in tissue repair, collagen synthesis, anti-inflammatory regulation, and antioxidant defence. Plasma GHK-Cu levels decline dramatically with age — from approximately 200 ng/ml at age 20 to under 80 ng/ml by age 60 — directly correlating with the systemic decline in repair capacity.
Why MG-LZ8™ comes first
GHK-Cu’s tissue repair mechanism depends on a coherent immune environment. Chronic immune dysregulation suppresses the fibroblast activity that GHK-Cu stimulates. MG-LZ8™’s MPO pathway modulation and Nrf2/SOD/GSH upregulation reduce the systemic oxidative burden that inhibits collagen synthesis. The immune terrain is cleared first. GHK-Cu then rebuilds tissue architecture on a stable biological foundation.
Protocol role
1.0–2.0mg per injection, 3–5 times per week. Stimulates fibroblast production of collagen and glycosaminoglycans, accelerates wound healing, and upregulates anti-inflammatory gene expression via NF-κB pathway modulation.
GHK-CuSub-CutaneousCopper TripeptideCollagen SynthesisMG-LZ8™ Foundation
RECHARGE · Cellular Energy Protocol
NAD+
Nicotinamide Adenine Dinucleotide · Injectable Grade · 500mg per vial
The compound
NAD+ (Nicotinamide Adenine Dinucleotide) is the master coenzyme of cellular energy metabolism — present in every cell of the human body and central to over 500 enzymatic reactions. It is the primary electron carrier in mitochondrial ATP synthesis and the essential cofactor for sirtuins (SIRT1–7), the longevity-associated deacetylase enzymes that govern DNA repair, circadian rhythm, inflammatory response, and cellular senescence. NAD+ levels decline by approximately 50% between the ages of 40 and 60.
The MG-LZ8™ dimension
MG-LZ8™ primes the mitochondrial environment before NAD+ delivery. Chronic immune activation suppresses mitochondrial biogenesis and accelerates NAD+ depletion via PARP1 hyperactivation. MG-LZ8™’s IL-2 restoration and Nrf2/SOD/GSH upregulation reduce the oxidative burden that consumes NAD+. The platform does not compete with RECHARGE — it protects and amplifies it. Signal first. Energy follows.
Protocol role
RECHARGE is the cellular energy foundation within the FRC protocol — 500mg per injection, 1–3 times per week. Restored NAD+ levels activate SIRT1-mediated mitochondrial biogenesis, enhance PARP1-dependent DNA repair, and reset the NAD+/NADH redox ratio that drives cellular respiration.
NAD+Injectable500mg vialSirtuin ActivationMG-LZ8™ Foundation
GROWTH · GH Optimisation Protocol
Ipamorelin + MG-LZ8™
Ghrelin Mimetic · Selective GH Release · Zero Cortisol Spike · Recovery & Anti-Aging
The peptide
Ipamorelin is a pentapeptide ghrelin mimetic (GHRP-3 family) that selectively stimulates the pituitary gland to release natural growth hormone. What sets it apart from every other GH peptide is its exceptional selectivity — it triggers a clean GH pulse without raising cortisol, ACTH, prolactin, or any other stress hormones, even at doses 200 times higher than those required for GH release. Half-life of approximately 2 hours. Sub-cutaneous injection, 100–300 mcg per dose, 2–3 times daily.
Why MG-LZ8™ comes first
Growth hormone response is directly suppressed by chronic immune activation and elevated pro-inflammatory cytokines — the pituitary becomes desensitised in a high-inflammation environment. MG-LZ8™’s 238× IL-2 mobilisation and three-pathway immune restoration clear the inflammatory terrain that blunts GH pulsatility. Ipamorelin then stimulates a clean, amplified GH pulse into a receptive biological environment. Signal first. Growth follows.
Ipamorelin
Selective GH Release
Ghrelin Mimetic
Zero Cortisol Spike
MG-LZ8™ Foundation
